Frontier Pharma Chronic, Acute and Neuropathic Pain Frontier Pharma Chronic, Acute and Neuropathic Pai

Frontier Pharma: Chronic, Acute and
Neuropathic Pain - GPCR and Nerve Growth
Factor-based therapies offer strong potential
in difficult-to-treat subtypes
“In the US, pain affects more people than cancer,
diabetes and heart disease combined, with an
estimated 100 million people having experienced at
least one chronic pain episode in the last 12 months,
at an annual cost of around $600 billion in medical
treatment and lost productivity.”
Summary
Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered
a disease in its own right, there is a growing body of evidence that substantiates chronic pain as a
disease, rather than just as a symptom of a primary cause. In the US, pain affects more people
than cancer, diabetes and heart disease combined, with an estimated 100 million people having
experienced at least one chronic pain episode in the last 12 months, at an annual cost of around
$600 billion in medical treatment and lost productivity.
Read Complete Report With TOC @ http://www.radiantinsights.com/research/frontier-
pharma-chronic-acute-and-neuropathic-pain-gpcr-and-nerve-growth
The pain therapeutics market has been largely characterized by only incremental product
innovation over the last decade, as most market segments continue to be dominated by long-
Follow Us: